Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  D'Antonio, Jason M ^a,b   van der Griend, Donald J ^a,b,d   Antony, Lizamma ^a   Ndikuyeze, George ^a   Dalrymple, Susan L ^a   Koochekpour, Shahriar ^c   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; SHORT HAIRPIN RNA; ANDROGEN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENICITY; CHROMOSOME DUPLICATION; CONTROLLED STUDY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WILD TYPE; X CHROMOSOME; ANIMAL; CHROMATIN IMMUNOPRECIPITATION; DNA SEQUENCE; DRUG EFFECT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; LENTIVIRINAE; METABOLISM; MOUSE MUTANT; MUTATION; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

MUS MUSCULUS;

ANDROGENS; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LENTIVIRUS; MALE; MICE; MICE, SCID; MUTATION; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, DNA;

EID: 77955401721     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011475     Document Type: Article

References (45)

1. Denmeade SR, Litvinov I, Sokoll LJ, Lilja H, Isaacs JT (2003) Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. Prostate 56: 45-53.
2. Whitacre DC, Chauhan S, Davis T, Gordon D, Cress AE, et al. (2002) Androgen induction ofin vitro prostate cell differentiation. Cell Growth Differ 13: 1-11.
3. Ling MT, Chan KW, Choo CK (2001) Androgen induces differentiation of a human papillomavirus 16 E6/E7 immortalized prostate epithelial cell line. J Endocrinol 170: 287-296.
4. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, et al. (2004) Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 64: 8867-8875.
5. Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, et al. (2007) Increased prostate cell proliferation and loss ofcell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci U S A 104: 12679-12684.
6. Simanainen U, Allan CM, Lim P, McPherson S, Jimenez M, et al. (2007) Disruption of prostate epithelial androgen receptor impedes prostate lobe-specific growth and function. Endocrinology 148: 2264-2272.
7. Isaacs JT, Isaacs WB (2004) Androgen receptor outwits prostate cancer drugs. Nat Med 10: 26-27.
8. Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, et al. (2006) PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability ofandrogen receptor. Prostate 66: 1329-1338.
9. Isaacs JT (2000) Apoptosis: translating theory to therapy for prostate cancer. J Natl Cancer Inst 92: 1367-1369.
10. Vander Griend DJ, Litvinov IV, Isaacs JT (2007) Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle 6: 647-651.
11. Denmeade SR, Isaacs JT (2002) A history of prostate cancer treatment. Nat Rev Cancer 2: 389-396.
12. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, et al. (2004) Androgen-independent prostate cancer is a heterogeneous group ofdiseases: lessons from a rapid autopsy program. Cancer Res 64: 9209-9216.
13. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, et al. (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate 57: 205-225.
14. Dehm SM, Tindall DJ (2007) Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol 21:2855-2863.
15. Liu W, Xie CC, Zhu Y, Li T, Sun J, et al. (2008) Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia 10: 897-907.
16. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ (2002) Disruption of androgen receptor function inhibits proliferation ofandrogen-refractory prostate cancer cells. Cancer Res 62: 1008-1013.
17. Yang Q, Fung KM, Day WV, Kropp BP, Lin HK (2005) Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int 5: 8.
18. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, et al. (2009) In vivo knockdown ofthe androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 15:39-47.
19. Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68: 3077-3080; discussion 3080.
20. Koochekpour S, Maresh GA, Katner A, Parker-Johnson K, Lee TJ, et al. (2004) Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. Prostate 60: 141-152.
21. International Standing Committee on Human Cytogenetic Nomenclature, Shaffer LG, Tommerup N (2005) ISCN 2005: an international system for human cytogenetic nomenclature (2005): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel; Farmington, CT, Karger 130 p.
22. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, et al. (2003) Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 54: 249-257.
23. Gao J, Arnold JT, Isaacs JT (2001) Conversion from a paracrine to an autocrine mechanism ofandrogen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 61: 5038-5044.
24. Khalili M, Mutton LN, Gurel B, Hicks JL, De Marzo AM, et al. (2010) Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia. Am J Pathol 176: 2259-2268.
25. Litvinov IV, Antony L, Isaacs JT (2004) Molecular characterization of an improved vector for evaluation ofthe tumor suppressor versus oncogene abilities ofthe androgen receptor. Prostate 61: 299-304.
26. van der Poel HG, McCadden J, Verhaegh GW, Kruszewski M, Ferrer F, et al. (2001) A novel method for the determination ofbasal gene expression oftissue-specific promoters: an analysis ofprostate-specific promoters. Cancer Gene Ther 8: 927-935.
27. Wang Q, Carroll JS, Brown M (2005) Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 19: 631-642.
28. Hanna N (1980) Expression of metastatic potential of tumor cells in young nude mice is correlated with low levels of natural killer cell-mediated cytotoxicity. Int J Cancer 26: 675-680.
29. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, et al. (2002) NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100: 3175-3182.
30. Hudson DL, Guy AT, Fry P, O'Hare MJ, Watt FM, et al. (2001) Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 49: 271-278.
31. Litvinov IV, De Marzo AM, Isaacs JT (2003) Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 88: 2972-2982.
32. Long RM, Morrissey C, Fitzpatrick JM, Watson RW (2005) Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (Lond) 108: 1-11.
33. Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT (2004) Structural basis ofandrogen receptor binding to selective androgen response elements. Proc Natl Acad Sci U S A 101: 4758-4763.
34. Verrijdt G, Haelens A, Claessens F (2003) Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genet Metab 78: 175-185.
35. Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD, et al. (2007) Apromoting role of androgen receptor in androgen-sensitive and-insensitive prostate cancer cells. Nucleic Acids Res 35: 2767-2776.
36. Jensen EV, Suzuki T, Kawashima T, Stumpf WE, Jungblut PW, et al. (1968) A two-step mechanism for the interaction of estradiol with rat uterus. Proc Natl Acad Sci U S A 59: 632-638.
37. Simental JA, Sar M, Lane MV, French FS, Wilson EM (1991) Transcriptional activation and nuclear targeting signals ofthe human androgen receptor. J Biol Chem 266: 510-518.
38. Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, et al. (2000) Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol Endocrinol 14: 1162-1174.
39. Huang YC, Hung WC (2006) 1,25-dihydroxyvitamin D3 transcriptionally represses p45Skp2 expression via the Sp1 sites in human prostate cancer cells. J Cell Physiol 209: 363-369.
40. Kang Z, Pirskanen A, Janne OA, Palvimo JJ (2002) Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem 277: 48366-48371.
41. Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, et al. (2003) A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4. J Biol Chem 278: 30828-30834.
42. Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, et al. (1991) Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 352: 497-505.
43. Sultan C, Paris F, Terouanne B, Balaguer P, Georget V, et al. (2001) Disorders linked to insufficient androgen action in male children. Hum Reprod Update 7: 314-322.
44. Zoppi S, Marcelli M, Deslypere JP, Griffin JE, Wilson JD, et al. (1992) Amino acid substitutions in the DNA-binding domain of the human androgen receptor are a frequent cause of receptor-binding positive androgen resistance. Mol Endocrinol 6: 409-415.
45. Leversha MA, Han J, Asgari Z, Danila DC, Lin O, et al. (2009) Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 15: 2091-2097.